On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review. In this video, recorded at the 41st Annual Congress of the European Association of ...
The ANDROMEDA trial compares alpha-emitting 225Ac-PSMA-617 and beta-emitting 177Lu-PSMA-617 with SBRT for recurrent oligometastatic prostate cancer. The trial builds on the LUNAR trial, which showed ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...
The Signatera ctDNA test predicts which MIBC patients benefit from adjuvant atezolizumab, showing significant DFS and OS improvements in MRD-positive patients. The IMvigor011 trial enrolled 760 ...
Experts recommend removing the black box warning on vaginal estrogen, citing overstated risks and emphasizing its benefits for menopausal women. Data shows significant cardiovascular benefits of HRT ...
NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...
Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...
The AUSCO trial showed a 94% success rate in achieving significant continence improvement in men with SUI using the artificial urinary sphincter. The study found no device infections and low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results